Navigation Links
The Astellas European Foundation Winner of Transplantation Grant 2011 Announced
Date:9/6/2011

GLASGOW, Scotland, September 7, 2011 /PRNewswire/ --

The Astellas European Foundation is delighted to announce the winner of the 2011 Transplantation Grant:

Dr Christian Toso of the University of Geneva, Switzerland

Last evening, the University's team, led by Dr Toso, received the grant of US$ 300,000 to support work on their project entitled 'Towards a tailored immuno-suppression after liver transplantation for hepatocellular carcinoma' at the Astellas European Foundation Award presentation.

Dr Ayad Abdulahad, Astellas European Foundation Trustee and Vice President Medical Affairs and Health Economics for Astellas Pharma Europe Ltd. commented, "We received many entries of a very high standard which covered a broad range of topics across Europe.  In the face of very strong competition the Jury chose Dr Toso's research based on its potential impact on clinical practice.  The team's aim is to tailor immunosuppressive strategy for individual patients with hepatocellular carcinoma. It is very exciting and, in the future, their results could possibly be applied to other cancers."

At the Award Presentation Event in Glasgow, UK, the Astellas European Foundation emphasised their continued and long term commitment to research and development in the field of transplant medicine.

Dr Toso said, "We thank the Astellas European Foundation for its generous support. Although liver transplantation is the most efficient treatment for patients with early  unresectable hepatocellular carcinoma, some 10% of recipients still experience recurrence after transplantation. The aim of our study is to define the ideal immunosuppression strategy, both clearing cancer cells and preventing rejection. Such a study has the potential to better tailor immunosuppression after liver transplantation for cancer, improve outcomes and qualify some currently excluded patients with more advanced HCCs for transplantation."

The Astellas European Foundation is a registered charity. It was established in 2005 with the  goal of providing support for programmes and activities that contribute to the advancement of an increasingly healthy society. The Astellas European Foundation Transplantation Grant supports basic medical and related scientific programmes which contribute to advancements in transplant medicine.  The winner of the grant was chosen by a Jury that includes independent European transplantation leaders.

http://www.astellas.com/eu


Notes to Editors

About The Astellas European Foundation

The Astellas European Foundation is a registered charity, established in 2005, with the long-term goal of providing support for programmes and activities that contribute to the advancement of an increasingly healthy society. The Astellas European Foundation is registered with the Charity Commission for England and Wales with number 1036344.

About Astellas Pharma Europe Ltd.

Astellas Pharma Europe Ltd., located in the UK, is a European subsidiary of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organisation is committed to becoming a global company by combining outstanding R&D and marketing capabilities and continuing to grow in the world pharmaceutical market. Astellas Pharma Europe Ltd. is responsible for 21 affiliate offices located across Europe, the Middle East, and Africa, an R&D site, and three manufacturing plants. The company employs approximately 4,000 staff across these regions.



'/>"/>
SOURCE Astellas European Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
2. Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide
3. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
4. Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
5. Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting
6. Astellas Announces Successful Completion of Initial Tender Offer for Shares of OSI and Announces Subsequent Offer Period
7. Agensys, an Affiliate of Astellas, Announces Initiation of Phase I Clinical Trial of AGS-16M8F for Renal Cancer
8. Astellas Awards Scholarships to 12 Transplant Recipients and Donors Who Embody Hope, Courage and Achievement
9. Astellas Mobilizes 1,300+ Employees in the Americas to Participate in First Annual Changing Tomorrow Day
10. Although NeurogesX/Astellass Qutenza is Only Approved for Postherpetic Neuralgia, Surveyed U.S. Physicians are Likely to Prescribe It for All Neuropathic Pain Types
11. Astellas Announces Retirement of Donald Rice and Appointment of Sef Kurstjens as CEO and President of Agensys, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Research and Markets has announced the addition ... 2016" report to their offering. ... The latest research Urinary Incontinence Drugs Price ... in the global Urinary Incontinence market. The research answers the ... drugs marketed for Urinary Incontinence and their clinical attributes? How are ...
(Date:2/23/2017)... Februar 2017 LG Innotek hat heute die ... Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls der Konkurrenz. ... zwischen 200 und 280 nm und eignet sich damit für ... ihre DNA zerstört. Das Produkt von LG Innotek erzeugt ... ...
(Date:2/23/2017)... Research and Markets has announced the addition of ... to their offering. ... latest research Menopause Drugs Price Analysis and Strategies - 2016, provides drug ... answers the following questions: What are the ... positioned in the Global Menopause market? What are the ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... ... Justice jointly issued a letter to withdraw previous guidance issued by ... gender identity. The guidance issued in May 2016 by the Obama Administration came ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, ... June: From Not to Hot,” which will begin airing on February 24, 2017. The ... millions from the 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier ...
(Date:2/23/2017)... ... ... Dr. David Mahon leads Siena Dental, a comprehensive dental practice located at ... Top Patient Rated Henderson Dentist by Find Local Doctors earlier this year. ... dentists who have earned high ratings and superior patient reviews from multiple credible sources. ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Center ... Rhode Island Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to present ... spectrum disorder (ASD) to see films in an environment that accommodates their unique ...
(Date:2/23/2017)... ... ... HealthPostures, the desk for standing designer headquartered in Prior Lake, Minnesota has announced ... and Garden Show which is being held February 24 through 26 and March 3 ... Convention Center. , From its broad line of sit stand desk solutions, HealthPostures ...
Breaking Medicine News(10 mins):